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Chikungunya fever has spread through several Indian 
Ocean islands and India, including popular travel destina-
tions. To compare usefulness of diagnostic tests and to 
understand reasons for the magnitude and severity of an 
outbreak, we used 3 diagnostic methods to test 720 sam-
ples from 680 patients returning to Europe from the Indian 
Ocean region in 2006. Chikungunya infection was conﬁ  rmed 
for 24.4% patients in the ﬁ  rst half of the year and for 9.9% 
in the second half. Reverse transcription–PCR was positive 
for all samples taken up to day 4 after symptom onset. Im-
munoﬂ  uorescence detected immunoglobulin (Ig) M on day 
1 and IgG on day 2 for some patients, and in all patients 
from day 5 onward. Soon after onset of symptoms, patients 
had IgG and IgM and high viral loads (some >109 copies/mL 
plasma). These data will help healthcare providers select 
diagnostic tests for returning travelers.
I
n 2005 and 2006 an outbreak of chikungunya fever of 
unprecedented magnitude spread over the western Indian 
Ocean region, including the Comoros Islands, Mauritius, 
Réunion Island, Madagascar, and the Seychelles (1,2). By 
October 2006 on Réunion Island alone, which has a popula-
tion of 760,000, at least 266,000 cases had been reported (3). 
The epidemic swept eastward into the Indian subcontinent, 
where by the end of the year it had caused >1.3 million cases; 
attack rates were 45% in some regions (4,5). By the begin-
ning of 2007, the epidemic was on the decline on La Réunion 
and the Seychelles (6), but it seems to be continuing in areas 
of India. New outbreaks have been reported from early 2007 
in Malaysia and mid 2007 in Indonesia (7,8).
Chikungunya virus (CHIKV) is an arthropod-borne 
RNA virus of the genus Alphavirus, family Togaviridae. 
Its genome is single stranded, of positive polarity, and 11.7 
kb long. Based on partial sequences of the envelope protein 
E1, CHIKV strains can be grouped into 3 distinct genetic 
lineages, which share a common ancestor in tropical Africa 
(9). The virus is transmitted to humans by numerous Aedes 
mosquito species, including Ae. aegypti and Ae. albopictus 
(2,10–12). The latter is thought to be less competent as a 
vector (2).
Strict mosquito-control measures in 2006 ameliorated 
the outbreaks on the Indian Ocean islands, but the spread 
of the same strain of CHIKV to India proves that the virus 
is not easy to contain (2,5). Tourists visiting these regions 
have imported the virus back to Europe and the United 
States, including regions of these countries in which the 
vector is known to be present (13,14).
CHIKV infection in humans is characterized by a sud-
den onset of fever, rash, and severe arthralgia (15–17). No 
speciﬁ  c treatment exists and symptoms are generally self-
limiting (16,18). Because in popular tourist destinations in 
the Indian Ocean region, the disease is endemic, along with 
malaria and dengue, CHIKV testing is now being conduct-
ed in outpatient settings. Antibody assays, virus isolation, 
and reverse transcription–PCR (RT-PCR) are available 
(19–21).
For clinical management of chikungunya, knowing 
which laboratory assays provide what information at given 
points of time during disease is helpful; cross-sectional de-
tection rates and kinetics of virologic parameters over time 
(virus RNA, immunoglobulin [Ig] M, and IgG) are crucial. 
Unfortunately, these data for CHIKV are minimal because 
studies on large patient cohorts were completed before rel-
evant laboratory tests, particularly RT-PCR, became avail-
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able. More recent studies have used such methods, but the 
numbers of studied patients have been limited (14,22,23). 
To provide support for the selection of diagnostic tests, we 
collected a cumulative ﬁ  gure of virologic parameters (vi-
ral RNA detection and antibody testing results over time) 
for the largest cohort of returning travelers studied to date. 
In addition, we sought possible reasons for the magnitude 
and severity of current outbreaks. Of relevance is a recent 
ﬁ  nding that Indian Ocean CHIKV strains display genetic 
characteristics in their structural E1 gene (22), especially at 
amino acid position 226. Similar to the related Semliki For-
est virus, in which a homologous mutation causes enhanced 
membrane fusion capacity in insect cells, the virus could 
have an advantage in insects or even in humans (22,24). 
We determined whether the mutation had an inﬂ  uence on 
viral loads in the patients in our cohort and how it was dis-
tributed geographically and temporally during 2006.
Materials and Methods
Patients and Clinical Samples
From January 1 through December 31, 2006, we tested 
720 samples from 680 patients at the Bernhard-Nocht In-
stitute for Tropical Medicine in Hamburg, Germany, for 
CHIKV infection. All had symptoms compatible with acute 
or recent CHIKV infection (sudden onset of fever, muscle 
and joint pain, headaches, rash) upon return to Europe (Ger-
many, n = 515; Belgium, n = 99; Switzerland, n = 42; Den-
mark, n = 22; Poland, n = 2). For 189 patients, exact travel 
destinations were reported: Madagascar (n = 9), Mauritius 
(n = 92), the Seychelles (n = 23), Réunion Island (n = 18), 
Bali (n = 2), Indonesia (n = 6), Sri Lanka (n = 5), India (n 
= 28), Malaysia (n = 2), Kenya (n = 1), and Thailand (n = 
3). Average ages of travelers to each country did not dif-
fer signiﬁ  cantly (analysis of variance F-test, p>0.05). For 
121 patients, exact dates of onset and sampling could be 
retrieved through voluntary questionnaires completed by 
telephone or fax after issuance of results. Age and sex dis-
tribution and travel histories for these patients are shown in 
Table 1. The day of onset of symptoms was deﬁ  ned as day 
0. All samples with possible CHIKV in 2006 were tested 
for IgG and IgM by indirect immunoﬂ  uorescence. During 
the ﬁ  rst half of 2006, all samples were tested by real-time 
RT-PCR in addition; however, in the second half of the 
year RT-PCR testing was restricted to samples from pa-
tients with acute infection only (on the basis of experiences 
from the ﬁ  rst 6 months as described below). Classiﬁ  cation 
of patients as having laboratory-conﬁ  rmed cases required 
either a positive RT-PCR or IgM result or an isolated IgG 
detection with at least a subsequent 4-fold increase in titer. 
The Statgraphics Plus 5.1 software package (Manugistics, 
Dresden, Germany) was used for all statistical analyses.
Indirect Immunoﬂ  uorescence
CHIKV strain S27 was grown on Vero cells at a multi-
plicity of infection of 0.5. Cells were spread on slides after 
24 h, air dried, and ﬁ  xed in ice-cold acetone. Serum samples 
were incubated for 1 h (IgG) or overnight (IgM) on ﬁ  xed 
cells. Antibodies were detected by anti-human IgG or IgM 
labeled with ﬂ  uorescein isothiocyanate (Siﬁ  n, Berlin, Ger-
many). For IgM testing, IgG was absorbed before testing 
by Biosorb resin (Biomed, Munich, Germany). Speciﬁ  city 
of antibodies was conﬁ  rmed by plaque-reduction neutral-
ization assay on a selection of samples (data not shown).
Nucleic Acid Testing
Two versions of real-time RT-PCR targeting the 
nsp1 gene of CHIKV were used: 1 for CHIKV in general 
and 1 adapted speciﬁ  cally to the current epidemic strain. 
Reaction conditions and oligonucleotides are listed in Table 
2. Quantiﬁ  ed in vitro–transcribed RNA was generated by 
cloning the RT-PCR target region in plasmid pCR2.1 (Invi-
trogen, Karlsruhe, Germany). Inserts together with a 5′-T7 
promotor sequence were ampliﬁ  ed with M13 plasmid-spe-
ciﬁ  c primers and transcribed into RNA by use of Megascript 
T7 reagents (Ambion, Austin, TX, USA). After DNase di-
gestion and afﬁ  nity puriﬁ  cation, transcripts were quantiﬁ  ed 
by photometer and used as quantiﬁ  cation standards.
Competitive internal controls were generated by over-
lap-extension PCR as described (25,26), by using ChikS/
ChikAs primers and mutagenic primers 5′-ATCGTTCGTT-
GAGCGATTAGCAGCAGGAAGTACCACTGCGTTT-
GCC-3′ and 5′-CTGCTAATCGCTCAACGAACGAT-
GCACTACCAATATCCAGGATGGTTG-3′. Mutated 
constructs were cloned into pCR2.1 and transcribed into 
RNA. Both assays did not cross-react with RNA extracted 
from serum samples with high titers or undiluted cell cul-
ture supernatants of the following viruses: Barmah Forest, 
dengue, Epstein-Barr, hepatitis C, herpes simplex type 1, 
human immunodeﬁ  ciency type 1, Japanese encephalitis, 
poliomyelitis type 1, Ross River, Sindbis, Venezuelan 
equine encephaltitis, West Nile, and yellow fever. Accord-
ing to series of parallel limiting-dilution experiments and 
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Table 1. Characteristics of chikungunya fever patients for whom 
travel and disease histories were known 
Age, y  Sex
Location visited  Mean Range M F
Mauritius (n = 69)  48.2 16–72 28 41
Seychelles (n = 17)  47.9 24–74 7 10
India (n = 15)  45.6 22–76 5 10
Réunion Island (n = 10)  47.3 17–78 3 7
Madagascar (n = 5)  45.2 29–53 4 1
Sri Lanka (n = 3)  38.7 34–48 3 0
Kenya (n = 1)  47 NA* 1 0
Indonesia (n = 1)  56 NA 0 1
Total (n = 121)  47.4 16–78 51 70
*NA, not applicable. RESEARCH
probit analysis (25,26), the general CHIKV assay detected 
3,844 RNA copies/mL of serum at >95% certainty (95% 
conﬁ  dence interval [CI] 2,834–6,832 copies/mL); the assay 
adapted to the current Indian Ocean strain detected 2,285 
copies/mL at 95% certainty (95% CI 1,694–5,326 cop-
ies/mL) (online Appendix Figure 1, available from www.
cdc.gov/EID/content/14/3/416-appG1.htm). On the whole 
panel of clinical samples described in this study, quantita-
tive correlation between both assays was close (regression 
analysis slope = 1, SD 0.04, p<0.001; online Appendix Fig-
ure 2, available from www.cdc.gov/EID/content/14/3/416-
appG2.htm).
Sequence Analysis
A fragment of the CHIKV E1 gene (positions 10265–
11158, GenBank accession no. DQ443544) was ampliﬁ  ed 
directly from patient plasma and sequenced. Sequencing 
was performed with a CEQ 8000 Genetic Analysis System 
(Beckman Coulter, Kreﬁ  eld, Germany) as recommended. 
Sequences were analyzed with Lasergene software pack-
age (DNASTAR, Madison, WI, USA).
Dengue Virus Testing
Serum samples were tested for dengue antibodies 
by an IgM μ-capture assay (Pan-Bio, Sinnamon Park, 
Queensland, Australia) and by indirect IgG immunoﬂ  uo-
rescence assay as described (27). All samples that were re-
portedly taken during the ﬁ  rst 12 days of illness were also 
tested for dengue virus by real-time RT-PCR (28).
Results
Cross-sectional Laboratory Results
CHIKV infection was laboratory-conﬁ  rmed for 152 
(22%) symptomatic patients and 188 (26%) samples. Me-
dian IgG titer for all 156 IgG-positive samples was 2,560 
(range 40–40,960). Median IgM titer for 136 IgM-positive 
samples was 320 (range 20–10,240). Median viral load for 
50 RNA positive samples was 1.7 × 105 RNA copies/mL 
(range 1 × 103–1.2 × 1010 RNA copies/mL). Table 3 sum-
marizes cross-sectional testing results for individual pa-
tients at time of ﬁ  rst visit.
In the ﬁ  rst half of the year, the rate of conﬁ  rmed infec-
tion for patients with suspected CHIKV was 24.4%; in the 
second half, 9.9%. Although the numbers of laboratory tests 
were comparable in the ﬁ  rst and second half of the year (396 
vs. 326), laboratory conﬁ  rmation rates in travelers were sig-
niﬁ  cantly higher in the ﬁ  rst half (χ2 test, p<0.001).
Cumulative Antibody Kinetics
We were able to retrieve 153 samples, exact informa-
tion on travel destination, onset of symptoms, and date 
of sampling for 121 patients (Figure 1). CHIKV IgG was 
found for 79% of patients (125 [81.7%] of 153 samples). 
The earliest sample with a detectable IgG titer had been 
drawn on day 2 after onset; the latest, on day 252. An iso-
lated IgG titer, i.e., no concomitant IgM, was detected in 
15 samples, 14 of which had been collected late after on-
set (median 86.5 days, range 39–252 days). The remaining 
sample, collected on day 2, was positive by RT-PCR.
Demonstrable CHIKV IgM was found in 111 (72.5%) 
of 153 samples from 88 (72.7%) patients. The earliest IgM-
positive result was obtained from a sample drawn on day 
1; the latest was obtained on day 170, from 1 sample. The 
only IgM sample with no concomitant IgG titer was drawn 
on day 1 after onset of fever; it was concomitantly positive 
by RT-PCR.
For 11 patients whose ﬁ  rst sample yielded antibodies, 
consecutive samples were available. All paired samples 
were drawn at least 14 days apart. The ﬁ  rst samples were 
collected after a median of 13 days from onset (range 5–68 
days), and all had IgM (median titer 320) and IgG (me-
dian titer 2,560). The second samples were collected after 
a median of 77 days from onset (range 20–207 days). Me-
dian IgG titer was 5,120; median IgM titer was 40. For 4 
patients, IgM was not detectable in the second serum sam-
ple, the earliest of which was drawn 50 days after onset of 
symptoms.
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Table 2. Real-time reverse transcription–PCR (RT-PCR) assay results for chikungunya virus (CHIKV) 
Oligonucleotide 
name  Purpose*  Sequence and label (5ƍ ĺ 3ƍ) 
Position (GenBank 
accession no.) 
ChikSI  Forward primer, general CHIKV assay  TGATCCCGACTCAACCATCCT  241–261 (AF369024) 
ChikSII  Forward primer, adapted assay for 
Indian Ocean strain 
CCGACTCAACCATCCTGGAT  246–265 (DQ443544) 
ChikAsI  Reverse primer, general CHIKV assay  GGCAAACGCAGTGGTACTTCCT  323–302 (AF369024) 
ChikAsII  Reverse primer, adapted assay for 
Indian Ocean strain 
GGCAGACGCAGTGGTACTTCCT  323–302 (DQ443544) 
ChikP  Detection probe, CHIKV  FAM-TCCGACATCATCCTCCTTGCTGGC-
BHQ1 
300–277 (AF369024) 
ICP  Detection probe, internal control  DyXL-ATCGTTCGTTGAGCGATTAGCAG-
BHQ2 
Not applicable 
*All oligonucleotides were used in the following assay: 25-μL reaction volume, 3 μL of RNA extract (Viral RNA Mini Kit, QIAGEN, Hilden, Germany), 
QIAGEN OneStep RT-PCR Kit, 600 nmol/L each primer, 200 nmol/L each probe. Cycling at 50°C for 30 min, 95°C for 15 min, 45 cycles each at 95°C for 
15 s and 58°C for 30 s, LightCycler (Roche, Mannheim, Germany). Chikungunya Fever in Travelers
Cumulative Diagnostic Parameters in 
Early Acute Illness
Of the 121 patients with complete histories, 45 (37.2%) 
had positive real-time RT-PCR results. To compare the ef-
ﬁ  ciency of diagnostic methods in acute disease, we selected 
all samples  collected during the ﬁ  rst 10 days of symptoms 
from patients in whom CHIKV was conﬁ  rmed by virus 
isolation or subsequent seroconversion (n = 63). RT-PCR 
was 100% positive up to day 4, regardless of antibody re-
sults (Figure 2). IgG and IgM were 100% positive from 
day 5 onward. IgM was detected only 1 day earlier than 
IgG. Overlapping RT-PCR and antibody results occurred 
from day1 to day 7. No positive RT-PCR result was found 
after day 7.
To assess whether CHIKV RNA detection may be in-
ﬂ  uenced by antiviral antibodies, we compared RNA con-
centrations in seronegative (n = 21) and seropositive (n = 6) 
samples, all collected within the ﬁ  rst 4 days of illness (Fig-
ure 2). Median RNA concentration was 9.85 × 107 copies/
mL in seronegative samples, which was signiﬁ  cantly higher 
than the 2.35 × 105 copies/mL found as median concentra-
tions in seropositive samples (p<0.017, analysis of variance 
F-test). To characterize the course of viremia in absence of 
antibodies, we plotted viral loads of all antibody-negative, 
PCR-positive samples against sampling days. The highest 
concentrations were found in samples drawn on day 0 with 
a mean of 1.2 × 109 RNA copies/mL (95% CI 8.2 × 108–1.6 
× 109 copies/mL) (Figure 2). Viral loads in later samples 
continuously decreased.
Efﬁ  ciency of Virus Isolation
To reassess the diagnostic value of classic virus iso-
lation techniques, we cultured 47 PCR-positive serum 
samples on Vero cells. All material had been frozen and 
thawed only 1 time before cell culture. Only 11 (23.4%) 
of 47 samples  yielded a virus isolate. Virus was isolated 
only in samples containing >1 × 107 RNA copies/mL (Fig-
ure 2). All culture-positive samples had been taken on or 
before the second day of fever, after a mean of 0.75 days 
from onset. Antibodies were not detectable in any of these 
samples, which suggests that infectivity in culture may be 
neutralized by antibodies.
Dengue Virus Co-infections
Dengue virus is endemic to parts of the Indian Ocean 
region and resembles CHIKV infection. All serum samples 
received in the ﬁ  rst half of 2006, including those from pa-
tients for whom travel and disease histories were incomplete, 
were tested for dengue virus. Only 3 of 368 patients had den-
gue IgG. Dengue IgM antibodies without IgG were found for 
2 additional patients, which suggests acute infection. Both 
patients had traveled to Mauritius. One patient had dengue 
IgM and CHIKV RNA. This patient had a long period of fe-
ver (38°C–40°C for 11 days) and severe arthralgia. Another 
patient had dengue IgM and anti-CHIKV virus IgM and IgG. 
This patient had severe arthralgia for 1 month.
E1 Protein Genotypes
We sequenced 40 PCR-positive samples, of which 
18 (45%) showed the original E1-226A genotype and 22 
(55%) had the E1-226V mutation (2 from Réunion Island, 
20 from Mauritius, all sampled in the ﬁ  rst half of 2006). 
Samples from India (n = 2) and from Sri Lanka (n = 2), 
which were collected in the second half of 2006, displayed 
the original E1-226A genotype. CHIKV viral loads among 
genotypes were compared (Figure 3). Median concentra-
tions (1.6 × 107 copies/mL for E1-226A; 1.6 × 105 cop-
ies/mL for E1-226V) were not signiﬁ  cantly different at the 
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Table 3. Detection of chikungunya virus infections in patients at initial examination, by laboratory test, 2006* 
IgG and IgM IgG only IgM only RT-PCR† RT-PCR only
Period No. (%) Total No.  (%) Total No. (%) Total No. (%) Total No. (%) Total
Jan–Jun 85 (23.1) 368 5 (1.4) 368 2 (0.5) 368 42 (11.8) 355 9 (2.5) 355
Jul–Dec 13 (4.2) 312 9 (2.9) 312 0 312 6 (30.0) 20 0 20
Total 98 (14.4) 680 14 (2.1) 680 2 (0.3) 680 48 (12.8) 375 9 (2.4) 375
*Ig, immunoglobulin; RT-PCR, reverse transcription–PCR. 
†Some patients were tested by using both RT-PCR and immunofluorescence; only RT-PCR results are given. 
Figure 1. Immunoglobulin (Ig) M and IgG titers in 153 samples from 
121 patients. Some patients are represented more than once if 
multiple specimens were submitted for testing. CHIKV, chikungunya 
virus.RESEARCH
95% conﬁ  dence level. To exclude an inﬂ  uence of CHIKV 
antibodies on this result, we analyzed samples without anti-
bodies separately. Again, the difference was not signiﬁ  cant 
(226A samples (n = 12), 5 × 107 copies/mL; 226V samples 
(n = 12), 2.5 × 106 RNA copies/mL).
Discussion
Chikungunya fever has become a major differential di-
agnosis, along with malaria and dengue fever, for ill travel-
ers returning to Europe from the Indian Ocean region. Be-
cause chikungunya fever has similar symptoms but requires 
different management than malaria and dengue, laboratory 
testing for CHIKV is now part of routine clinical decision 
making. Our analysis of baseline virologic ﬁ  ndings by us-
ing a modern repertoire of diagnostic tests comprised the 
largest cohort of travelers returning from sites of the cur-
rent epidemic. Tourists are of particular interest because 
they are not seen in the context of community outbreaks, 
and thus, their diagnoses need individual laboratory conﬁ  r-
mation. The large number of cases in our study enabled us 
to establish a gapless time course of virologic parameters 
by cumulating single- and dual-point laboratory determina-
tions from individual infected travelers.
Cross-sectional laboratory data provided a good in-
dication of the extent of this large outbreak of a usually 
underdiagnosed arbovirus infection in travelers. In the 
ﬁ  rst half of 2006, as much as 24.4% clinically suspected 
cases of CHIKV infection could be conﬁ  rmed. This pre-
dictive value of clinical diagnosis is impressive compared 
with that for suspected dengue virus infection in travelers 
(29,30). The decrease to 9.9% in the second half of 2006 is 
probably a reﬂ  ection of the decreasing CHIKV activity in 
tourist destinations, along with a shift to the Indian subcon-
tinent where tourism is less concentrated.
In the cumulative time course, anti-CHIKV IgG and 
IgM antibodies were detected soon after onset of symp-
toms. They were present in all patients in whom acute 
infection was conﬁ  rmed after 5 days. IgG was present so 
early that additional testing for IgM provided only lim-
ited additional sensitivity for detecting acute cases. Most 
likely this ﬁ  nding was caused not by low sensitivity of our 
IgM assay but by an unusually early IgG response. One 
reason for early IgG ﬁ  ndings could be lack of speciﬁ  city 
of the applied immunoﬂ  uorescence assay. However, we 
have shown recently that indirect immunoﬂ  uorescence is 
a sensitive and speciﬁ  c method for determining antibodies 
against CHIKV (N. Litzba et al., unpub. data). Moreover, 
we have conﬁ  rmed speciﬁ  city of our immunoﬂ  uorescence 
assay results by retesting a subset of serum samples by 
plaque-reduction neutralization test (data not shown); all 
antibody-positive samples subjected to this test had posi-
tive results. Finally, because most patients resided in Ger-
many, where alphaviruses are not endemic, preexisting 
antibodies are unlikely. We must therefore assume that 
the IgG results are technically valid. An explanation for 
early IgG production would be the presence of unusually 
high presymptomatic viremia that provided an early anti-
gen stimulus for antibody formation.
Cell culture in our study was not particularly diagnos-
tic. It was rather insensitive (23.4%) compared with RT-
PCR, and the presence of antibody seemed to prevent isola-
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Figure 2.  A) Rates of positive results from assays for immunoglobulin 
(Ig) M, IgG, and virus RNA, ﬁ  rst 10 days of symptoms. Numbers 
above bars are numbers of samples (and patients). B) Left panel, 
viral loads in serum or plasma in antibody-negative, PCR-positive 
patients (n = 21, left column) and in antibody-positive, PCR-positive 
patients (n = 6, right column). All patients were sampled during ﬁ  rst 3 
days of symptoms. Right panel, viral loads in all antibody-negative, 
PCR-positive samples. Error bars represent interquartile ranges. C) 
Viral loads, antibodies, and virus isolation from 47 samples positive 
by reverse transcription–PCR (RT-PCR). Virus isolation + indicates 
isolation success as conﬁ  rmed by cytopathogenic effect and direct 
immunoﬂ  uorescence assay. Antibody detection + indicates an IgG 
or IgM titer >10 by immunoﬂ  uorescence assay.Chikungunya Fever in Travelers
tion of virus. In successful cultures, cytopathic effects were 
not observed before 3–4 days of incubation, often requiring 
at least 1 passage, which made time for culture longer than 
time to seroconversion. Nevertheless, culture is essential 
for more speciﬁ  c investigation such as virus neutralization 
tests, as well as for ecologic and basic research. For clini-
cal virus detection, RT-PCR seemed to be the method of 
choice. Our study provides 2 alternative real-time RT-PCR 
protocols that have analytical performance comparable to 
that of major diagnostic PCR systems (25,26); each proto-
col has been clinically evaluated on our whole cohort.
Apart from practical diagnostic implications, our ﬁ  nd-
ings identify important questions for future research. As an 
example, courses of antibodies and viremia were different 
from those of dengue virus infections (27,31). Probably 
the most important difference was an early IgG response 
to CHIKV, compared with a clear delay of IgG (appear-
ing after IgM) in most acute cases of primary dengue vi-
rus infection. For a substantial fraction of patients, dengue 
IgG is not detected until after 2 weeks of illness (27,31). 
One could speculate that the reason for this difference is 
the different tropism of each virus. Dengue virus infects 
predominantly monocytes (31) and thereby may induce 
a relevant, short-term immunosuppression (32). CHIKV 
probably does not share this tropism (33), although the pri-
mary target site of CHIKV infection is unclear. Whether 
co-infection with dengue and CHIKV would lead to altered 
symptoms is another question; 2 patients in our study had 
this co-infection. Their disease courses may be more severe 
or prolonged than those of most patients (17), but detailed 
and controlled studies on more patients are needed.
Data on viral load determined in this study are crucial 
for infection control. During their ﬁ  rst few days of illness, 
our patients had tremendous virus concentrations, some-
times >109 copies/mL of plasma. Such high viral loads are 
uncommon with other arboviral diseases (34–36) and would 
make CHIKV prone to nosocomial transmission, e.g., by 
needle-stick injury or mucous membrane exposure. Indeed 
such an event has already been documented (23). Blood and 
other body ﬂ  uids of CHIKV patients should be considered 
infectious during the ﬁ  rst week of symptoms. We cannot 
determine from this study whether the potential infectiv-
ity of CHIKV may also become important in the context of 
transfusion, because we analyzed only symptomatic patients. 
However, virus concentrations in our patients were already 
decreasing when symptoms were detected, and therefore a 
high viremia in presymptomatic patients seems likely. None 
of our patients had antibodies on day 0, and presymptomatic 
patients would therefore be highly infectious. The issue of 
transfusion transmissibility of CHIKV deserves intensive in-
vestigation. Targeted interventions like on Réunion Island, 
where blood donation was suspended during the epidemic 
and blood was imported from France (37), are not an option 
in India or Southeast Asia.
Why such a large epidemic of CHIKV infections could 
occur and why courses of disease were so unusually severe 
are unclear. A previous study recognized an A226V ex-
change in the E1 envelope glycoprotein for the ﬁ  rst time in 
CHIKV and found it to increase over time in isolates from 
Réunion Island (22). In the related Semliki Forest virus, a 
corresponding mutation conferred a replication advantage 
in cholesterol-depleted insect cells (24), which for the virus 
would implicate an advantage in its reservoir. In addition 
to the above ﬁ  ndings of Schuffenecker et al, we could con-
ﬁ  rm presence of the mutation on Mauritius, where a larger 
part of our patients had visited. However, viruses isolated 
in the late phase of our study (September to December 
2006) from patients returning from India and Sri Lanka, 
respectively, did not show the mutation but were otherwise 
clearly related to the Indian Ocean strain. The signiﬁ  cance 
of the mutation thus remains uncertain, and functional stud-
ies are needed. Conﬁ  rmation of this or other genetic con-
nections would provide another example of minor genetic 
differences that account for major changes of an arthropod 
virus. After the past and ongoing experiences with agents 
such as the coronavirus of severe acute respiratory syn-
drome and avian inﬂ  uenza viruses, the CHIKV epidemic 
provides more proof of the importance of research into the 
ecology of emerging and reemerging diseases.
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Figure 3. Viral loads for all PCR-positive samples (left panel) and 
immunoglobulin (lg)–negative/PCR-positive samples (right panel), 
depending on types of mutation (alanine or valine at amino acid 
position 226 of the envelope 1 protein, as shown on the x-axis). 
Boxes represent the innermost 2 quartiles of data; horizontal line 
shows the mean; whiskers represent the outermost 2 quartiles.RESEARCH
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